Reshape Lifesciences Q2 EPS $(0.06) Up From $(1.08) YoY, Sales $1.97M Miss $2.21M Estimate
Reshape Lifesciences Q2 EPS $(0.06) Up From $(1.08) YoY, Sales $1.97M Miss $2.21M Estimate
reshape lifesciences Q2每股收益为$(0.06)，同比$(1.08)增长，销售额197万美元，未达到221万美元的预估。
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.06) per share. This is a 94.44 percent increase over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $1.97 million which missed the analyst consensus estimate of $2.21 million by 11.09 percent. This is a 12.82 percent decrease over sales of $2.25 million the same period last year.
Reshape Lifesciences（纳斯达克：RSLS）报告每股亏损$（0.06）。相比去年同期的每股亏损$（1.08），增长了94.44％。公司本季度销售额为197万美元，低于分析师预期的221万美元，下降了11.09％。这是与去年同期的销售额225万美元相比下降了12.82％。
资讯热榜
更新时间